Article, News
The cancer-fighting tech disabling ‘force fields’ around tumours
SX-listed biotech Prescient Therapeutics has unveiled the second component of its CellPryme cell therapy enhancement platform on stage at the prestigious CAR-TCR Summit in Boston….
Article, News
Prescient Therapeutics debuts CellPryme-A at world’s largest CAR-TCR meeting in Boston
At the world’s largest CAR-TCR meeting, Prescient Therapeutics (ASX: PTX) has debuted CellPryme-A, which is a novel adjuvant designed to be administered to cancer patients in combination…
Article, News
Prescient unveils latest big hitter CellPryme-A at prestigious Boston CAR-TCR meeting
Prescient has unveiled the latest technology in its cancer-fighting portfolio CellPryme-A at the 7th annual CAR-TCR Summit in Boston, the world’s pre-eminent forum in the CAR…
Article, News
Biotechnology investing for the social good – making money and a difference
There are many foundations and charities which aim to tackle health conditions through funding medical research to develop better treatment options, improve patient outcomes and…
Article, News
Prescient Therapeutics unveils novel adjuvant for enhancing cellular immunotherapy: CellPryme-A
CellPryme-A is the latest in a portfolio of platform cell technologies that can not only create innovative programs for Prescient, but are also enabling technologies…
Article, News
Prescient (ASX:PTX) unveils exciting CellPryme-A data at world’s largest CAR-TCR meeting
Prescient Therapeutics (ASX: PTX) has presented exciting new data on CellPryme-A at the 7th Annual CAR-TCR Summit in Boston, MA. The summit is one of the…
Article, News
HealthKick Podcast: PTX partners with the US’s largest cancer centre on personalised treatment
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. …
Article, News
Prescient joins up with renowned US cancer centre in fight against blood cancer
Prescient will join with the US’s largest cancer centre with the goal of creating best-in-class, adaptable CAR-T cell therapies to treat hematological malignancies. Clinical stage…
Article, News
Prescient Therapeutics (ASX:PTX) teams up with prestigious cancer centre in the US
Prescient Therapeutics (ASX: PTX) takes a crucial step in advancing its next-generation cell therapy platform, OmniCAR. The clinical-stage oncology player entered into a strategic agreement with The…
Article, News
Prescient Therapeutics to collaborate with largest cancer centre in the US to develop blood cancer treatment
“We believe that OmniCAR is a transformational platform for cellular immunotherapy, and we look forward to testing the potential of this promising TCR-like binder for…